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Abstract
Background: Regional pain in the hip in adults is a common cause of a general practitioner visit. A
considerable part of patients suffer from (greater) trochanteric pain syndrome or trochanteric bursitis.
Local corticosteroid injections is one of the treatment options. Although clear evidence is lacking, small
observational studies suggest that this treatment is effective in the short-term follow-up. So far, there are
no randomised controlled trials available evaluating the efficacy of injection therapy.
This study will investigate the efficacy of local corticosteroid injections in the trochanter syndrome in the
general practice, using a randomised controlled trial design. The cost effectiveness of the corticosteroid
injection therapy will also be assessed. Secondly, the role of co-morbidity in relation to the efficacy of local
corticosteroid injections will be investigated.
Methods/Design: This study is a pragmatic, open label randomised trial.
A total of 150 patients (age 18–80 years) visiting the general practitioner with complaints suggestive of
trochanteric pain syndrome will be allocated to receive local corticosteroid injections or to receive usual
care. Usual care consists of analgesics as needed. The randomisation is stratified for yes or no co-morbidity
of low back pain, osteoarthritis of the hip, or both. The treatment will be evaluated by means of
questionnaires at several time points within one year, with the 3 month and 1 year evaluation of pain and
recovery as primary outcome. Analyses of primary and secondary outcomes will be made according to the
intention-to-treat principle. Direct and indirect costs will be assessed by questionnaires. The cost
effectiveness will be estimated using the following ratio: CE ratio = (cost of injection therapy minus cost
of usual care)/(effect of injection therapy minus effect of usual care).
Discussion: This study design is appropriate to estimate effectiveness and cost-effectiveness of the
injection therapy. We choose to use a pragmatic study design and are thus not able to study specific effects
of the injection with corticosteroids. A distinction between placebo effect of the injection and specific
effects of the corticosteroids is therefore not possible.
Trial Registration: The trial is listed in the Dutch Trial Registry with the number ISRCTN16994576
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One of the more common pain syndromes of the in the
hip in adults is known as trochanteric pain syndrome
(TPS) or trochanteric bursitis. It is considered to have the
following characteristics: chronic, intermittent pain at the
lateral site of the upper limb, sometimes radiating to the
lateral aspect of the hip or lateral thigh and increasing at
physical activity [1-4]. Lying on the affected site increases
the pain and can thereby disturb sleep and/or rest. At
physical examination palpation of the greater trochanter
is painful [1-4].
The prevalence is higher among females than among
males (rate 4:1) and the incidence is highest between the
ages 40 to 60 years [4,5]. A recent prospective study in a
Dutch general practice population showed an incidence
of 5.6 patients per 1000 adults in one year (unpublished
pilot data). In a retrospective study, Lievense et al. found
an incidence of 1.8 per 1000 in one year [5].
Earlier, the same clinical manifestations were known as
trochanteric bursitis, although clinical manifestations of
inflammation almost never occur [1,2,4]. Tendinitis of
the insertion of the m. gluteus medius is suggested as
another cause of pain at this site. It might also be a com-
bination of bursitis and tendinitis. Because the exact aeti-
ology is not known, Collee et al. suggested in 1991 to
classify the clinical manifestations as "greater trochanter
syndrome" [6].
Observational studies showed that in most of the cases
with local pain at this site co-morbidity exists. About two-
thirds of the patients with TPS have also low back pain or
osteoarthritis of the hip [1,3,6,7].
Many GPs inject corticosteroids combined with an anaes-
thetic agent at the most painful site with the expectation
that the pain will decrease. There is no conclusive evi-
dence that these injections are effective, although small
observational studies suggest that injections with corticos-
teroids are effective in the short-term follow-up [2,5,7,8].
No randomised controlled trials are available evaluating
the benefit of injection therapy for this disorder. Other
common treatment options are pain relief with analgesics,
physiotherapy, a surgical release of the iliotibial tract,
removal of the bursa, or a trochanteric reduction osteot-
omy [9].
This study we will investigate the efficacy and cost effec-
tiveness of local corticosteroid injections in TPS, using a
randomised controlled trial design. We also investigate




This study is a pragmatic, open label randomised trial.
The local Medical Ethics Committee of the Erasmus Uni-
versity Medical Center, Erasmus MC, has approved the
trial. The trial is included in the Dutch Trial register
(ISRCTN 16994576).
All patients will give written informed consent.
Patient selection
GPs participating in the HONEUR research network of the
Erasmus MC and other interested GPs in the area will be
invited to participate in the study. The HONEUR GP
research network consists of 40 GP practices which are
connected to the Department of General Practice in order
to participate in regular research projects. They will be
asked to select patients aged 18 to 80 years visiting the GP
with the following symptoms: pain persisting for more
than one week in the lateral region of the hip or thigh with
tenderness at palpation of the greater trochanter with one
of the two following characteristics [1-4,10]:
1). Severe pain at palpation of the greater trochanter, but
uncertainty as to whether the patient recognizes the pain
as that for which he or she visits the GP.
2). Local tenderness when the area of the great trochanter
is palpated and the patient recognizes the pain as that for
which he or she visits the GP.
Excluded are patients who are unable to understand the
Dutch questionnaires, patients who have consulted the
GP with the same complaints in the previous year and had
any intervention, or are operated on in the same region, or
have systemic neurological or rheumatologic disorders.
Procedures
Patients who are eligible for the study and show interest
to participate will receive written study information from
their GP, as well as the baseline questionnaire and the
informed consent form. If they show interest the GP will
fax their contact data to the researcher together with the
findings of physical examination on a standardized form.
One of the investigators will contact the patient to ask if
they have any additional questions and will assess the
suitability to participate in the study. If the patient still
wants to participate and is eligible, we ask them to return
the baseline questionnaire and informed consent form.
When we receive the baseline questionnaire, the patient
will be classified as having comorbidity or not. If the ques-
tion: "Do you suffer from low back pain" is answered pos-
itively as often or continuous, we classify the patient asPage 2 of 5
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osteoarthritis of the hip, using history and physical exam-
ination (painful or decreased internal rotation and flexion
of the hip as performed by the GP) are used to decide
whether the patient has osteoarthritis of the hip as comor-
bidity [11].
Randomisation
After receiving the baseline questionnaire and informed
consent, an independent person will randomise each
patient based on computerized randomisation lists to
either receive the injection therapy or the usual care, con-
sisting of analgesics as needed. This randomisation is
stratified for yes or no comorbidity and uses randomisa-
tion block sizes of ten, yielding four strata: one lacking
comorbidity, one with low back pain, one with osteoar-
thritis, and one stratum with both.
Intervention
The GP and the patient will be informed about the treat-
ment that the patient will be given as soon as randomisa-
tion has taken place. The GPs participating in the study
have been trained by us to give the injection according to
a standard procedure: i.e. to use 40 mg triamcenolon ace-
tate combined with lidocaine 1 or 2% in a 5 ml syringe.
They are trained to mark the most painful point with a
pen or pencil and desinfect the site. The needle is inserted
perpendicular to the skin and directed down to the point
of maximal tenderness, 1 ml of the substance will be
injected at that point, then the needle should be moved to
another place in the painful area and the same procedure
should be repeated until the syringe is empty. In case of
lack of efficacy, or only temporary effect, this procedure
may be repeated after a period of 3 weeks up to 3 months
After the injection the GP will fax us a form with details of
the injection given, e.g. the volume that is injected, if the
injection was painful, or if there was pain relief after injec-
tion or direct side effects.
The control group will receive usual care consisting of
analgesics as needed; all patients are free to receive addi-
tional treatment from a physiotherapist, although this is
not advocated by the investigators.
Questionnaires
The primary outcome measurements will be experienced
recovery at 3 months and at 1 year, measured on a 7-point
Likert scale (1 = fully recovered till, 7 = worse than ever)
and severity of pain during the last week measured with a
numeric rating scale (0 = no pain, 10 = worst conceivable
pain). Medical consumption of the patient (e.g. medica-
tion, visits to the GP or physiotherapist, hospital treat-
ment and diagnostic tests) will be measured as direct cost.
The PRODISC questionnaire will be used to measure the
cost effectiveness and will measure the indirect costs,
expressed in work staff absence and loss of productivity in
paid work, or loss of productivity in not-paid work [12].
The WOMAC (Western Ontario and McMaster University
Osteoarthritis Index) is recommended by the Osteoarthri-
tis Research Society for use in clinical trials in people with
hip osteoarthritis to measure pain and disabilities [13].
The HOOS (hip disability and osteoarthritis outcome
score) [14] is developed as an extended version of the
WOMAC, to evaluate the whole domain of patient-rele-
vant outcome in young and active patients and is recently
validated in the Dutch language [15]. The HOOS consists
of 5 subscales; Pain, other Symptoms, Function in daily
living (ADL), Function in sport and recreation (Sport/Rec)
and hip-related Quality of life (QOL). Both the WOMAC
and HOOS will be used in this study. We use the EuroQol
(EQ5D) as instrument to measure quality of life [16].
Finally, we ask the patients who received an injection, to
report any side effects of the injection. Table 1 shows the
timing of measurements.
Sample size
The sample size was calculated to detect an increase in
recovery rate of 25% in the intervention group after three
months of follow-up (45% recovery in the control group
versus 70% recovery in the intervention group). With
power 0.8 and alpha 0.05 (two-sided tested) and with a
dropout rate of 10%, a total number of 75 patients in each
group are needed.
Data analyses
Difference between the groups in the primary outcome
will be analysed based on the basis of the "intention-to-
treat" principle. Differences in continuous outcome meas-
Table 1: Timing of study questionnaires
baseline 6 weeks 3 months 6 months 9 months 12 months
Severity of pain: VAS (1–10) x x x x x x
Experienced recovery: Likert (1–7) x x x x x
HOOS including WOMAC x x x x x x
Prodisq + medical consumption x x x x x
EQ 5 D x x x x x
Side effects of injection x x x xPage 3 of 5
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regression techniques and differences in dichotomous
outcomes (recovery dichotomised to totally recovered or
almost totally recovered versus slightly recovered and less)
will be analysed with logistic regression techniques. Base-
line differences between the groups will be assessed and
checked whether these influence the outcome of the
study. Baseline variables that change the outcome by 10%
or more will be regarded as confounders and will there-
fore be added to the regression models.
Regression models will also be used to study effect modi-
fication of comorbidity. A cost-effectiveness analyses will
be performed from a social and a patient perspective,
looking at differences in direct and indirect health care
cost between the two groups.
If the trial does not show a difference in disease parame-
ters (VAS and WOMAC) and quality of life (EuroQol)
between the groups, the analysis will be reduced to a cost
minimisation analysis. This form of analysis evaluates the
efficacy of treatment based solely on direct and indirect
costs. If the study does find a positive difference in disease
parameters and/or quality of life in the injection group, a
cost-effectiveness ratio can be determined.
Discussion and current status
In this study design we compare two types of therapy
which are frequently used in general practice. This study
design is appropriate to estimate effectiveness and cost-
effectiveness of the injection therapy. We choose to use a
pragmatic study design and are thus not able to study spe-
cific effects of the injection with corticosteroids. A distinc-
tion between placebo effect of the injection and specific
effects of the corticosteroids is therefore not possible.
The study is executed in general practice and may there-
fore not apply to patients in secundary care.
No disease specific questionnaires are available for this
disorder. Therefore generic outcome measures (recovery
and pain severity) were chosen as primary outcome meas-
ures. However, region specific questionnaires for osteoar-
thritis were included as secondary outcome measures.
These questionnaires allow us to analyse subscales like for
instance the WOMAC pain and the WOMAC function;
subsequently osteoarthritis specific questions on stiffness
(WOMAC stiffness) can validly be omitted.
Patients included in our trial have symptoms of TPS
solely, or have these symptoms in co-occurrence with low-
back pain or osteoarthritis of the hip. To include patients
with such co-morbidity maybe questionable because the
TPS may be due to such morbidity. Therefore injection
therapy for TPS in such morbidity possibly shows differ-
ent effectiveness. We chose to include these patients
because in common practice these patient also receive
injection therapy. We, however, used a design in which we
stratify for co-morbidity or not.
The current status of the study is that of a total of the 80
GPs participating in the study. However, until now only
43 GPs included 90 patients. The total study population is
expected to be recruited by February 2008. The first short-
term results (3 months of folluw-up) will be available at
mid-2008.
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